Literature DB >> 15059888

Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells.

Sophie E Polo1, Stamatios E Theocharis, Jerzy Klijanienko, Alexia Savignoni, Bernard Asselain, Philippe Vielh, Geneviève Almouzni.   

Abstract

Histone synthesis and chromatin assembly are mainly associated with DNA replication and are thus intimately involved in cell cycle regulation. The expression of key components involved in these events in human cells was studied in relation to cell-proliferative status. Among several chromatin assembly factors, chromatin assembly factor (CAF)-1 stood out as the most discriminating marker of the proliferative state. We show, using both immunofluorescence and Western blot analysis, that the expression of both CAF-1 large subunits, p150 and p60, is massively down-regulated during quiescence in several cell lines. Upon exit from the quiescent state, the CAF-1 subunits are re-expressed early, before DNA replication. The amounts of either total or chromatin-associated pools of CAF-1 proteins correlate directly with cell proliferation. Regulation of CAF-1 expression is partly controlled at the RNA level, as shown by quantitative reverse transcription-PCR and Northern blot experiments. Biological material from benign and malignant human breast tumors analyzed by immunocytochemistry and immunohistochemistry exhibits a strong positive correlation between CAF-1 p60 expression and the following proliferation markers: S-phase fraction (r = 0.84, P < 0.0001); Ki-67 (r = 0.94, P < 0.0001); and proliferating cell nuclear antigen (r = 0.95, P = 0.0001). We discuss the advantages of using CAF-1 to assess cell proliferation. High CAF-1 p60 levels are also shown to be associated with various prognostic factors. Our data highlight the precise association of CAF-1 expression with the proliferative state and validate the use of this factor as a useful proliferation marker and prognostic indicator in malignant and benign breast lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059888     DOI: 10.1158/0008-5472.can-03-2893

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Functional conservation and specialization among eukaryotic anti-silencing function 1 histone chaperones.

Authors:  Beth A Tamburini; Joshua J Carson; Melissa W Adkins; Jessica K Tyler
Journal:  Eukaryot Cell       Date:  2005-09

Review 2.  Beyond the histone tale: HP1α deregulation in breast cancer epigenetics.

Authors:  Johan Vad-Nielsen; Anders Lade Nielsen
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  iAMPlified gene expression offers new insights in B cell precursor leukemia subtype.

Authors:  Panagiotis Ntziachristos
Journal:  Leuk Lymphoma       Date:  2020-02-03

4.  A Potential New Mechanism of Arsenic Carcinogenesis: Depletion of Stem-Loop Binding Protein and Increase in Polyadenylated Canonical Histone H3.1 mRNA.

Authors:  Jason Brocato; Danqi Chen; Jianli Liu; Lei Fang; Chunyuan Jin; Max Costa
Journal:  Biol Trace Elem Res       Date:  2015-04-21       Impact factor: 3.738

5.  Histone chaperone ASF1B promotes human β-cell proliferation via recruitment of histone H3.3.

Authors:  Pradyut K Paul; Mary E Rabaglia; Chen-Yu Wang; Donald S Stapleton; Ning Leng; Christina Kendziorski; Peter W Lewis; Mark P Keller; Alan D Attie
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

6.  The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.

Authors:  Rocío Montes de Oca; Zachary A Gurard-Levin; Frédérique Berger; Haniya Rehman; Elise Martel; Armelle Corpet; Leanne de Koning; Isabelle Vassias; Laurence O W Wilson; Didier Meseure; Fabien Reyal; Alexia Savignoni; Bernard Asselain; Xavier Sastre-Garau; Geneviève Almouzni
Journal:  Mol Oncol       Date:  2014-11-20       Impact factor: 6.603

7.  Chromatin Regulators as a Guide for Cancer Treatment Choice.

Authors:  Zachary A Gurard-Levin; Laurence O W Wilson; Vera Pancaldi; Sophie Postel-Vinay; Fabricio G Sousa; Cecile Reyes; Elisabetta Marangoni; David Gentien; Alfonso Valencia; Yves Pommier; Paul Cottu; Geneviève Almouzni
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

8.  Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation.

Authors:  Persis P Wadia; Marc Coram; Randall J Armstrong; Michael Mindrinos; Atul J Butte; David B Miklos
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

9.  Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients.

Authors:  Massimo Mascolo; Maria Luisa Vecchione; Gennaro Ilardi; Massimiliano Scalvenzi; Guido Molea; Maria Di Benedetto; Loredana Nugnes; Maria Siano; Gaetano De Rosa; Stefania Staibano
Journal:  BMC Cancer       Date:  2010-02-24       Impact factor: 4.430

10.  Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.

Authors:  Marc A Bollet; Alexia Savignoni; Leanne De Koning; Carine Tran-Perennou; Catherine Barbaroux; Armelle Degeorges; Brigitte Sigal-Zafrani; Geneviève Almouzni; Paul Cottu; Rémy Salmon; Nicolas Servant; Alain Fourquet; Patricia de Cremoux
Journal:  Breast Cancer Res       Date:  2009-07-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.